IL-1β, IL-1 receptor antagonist and soluble type II IL-1 receptor in synovial fluid of patients with temporomandibular disorders

被引:20
作者
Tominaga, K
Habu, M
Sukedai, M
Hirota, Y
Takahashi, T
Fukuda, J
机构
[1] Kyushu Dent Coll, Dept Oral & Maxillofacial Surg 1, Kitakyushu, Fukuoka 8038580, Japan
[2] Kyushu Dent Coll, Dept Oral & Maxillofacial Surg 2, Kitakyushu, Fukuoka 8038580, Japan
关键词
interleukin-1; beta; interleukin-1 receptor antagonist; receptor; temporomandibular disorder;
D O I
10.1016/j.archoralbio.2003.12.008
中图分类号
R78 [口腔科学];
学科分类号
1003 [口腔医学];
摘要
Among the members of the interleukin-1 (IL-1) family, IL-1, which is a major agonist, has been detected in synovial. fluid (SF) of the temporomandibular joint (TMJ) of patients with temporomandibular joint disorders (TMD). However, there is little knowledge regarding suppressive molecules, such as IL-1 receptor antagonist (IL-1ra) and the soluble form of type 11 IL-1 receptor (sIL-1RII), in TMD patients. The aim of this study was to investigate the levels of IL-1beta, IL-1ra and sIL-1RII in the TMJ SF of patients with TMD and their relationship. Fifty-two SF samples from TMD patients and nine samples from asymptomatic volunteers were examined. Detected levels of IL-1beta and sIL-1RII were significantly higher in the TMD group compared with the volunteer group. There was no significant difference in IL-1ra levels between the TMD and volunteer groups. The IL-1beta/IL-1ra ratio in the TMD group, however, was higher than that in the volunteer group. In the TMD group, positive correlations were found between IL-1beta and IL-1ra, IL-1ra and sIL-1RII, and IL-1beta and sIL-1RII. In addition to increased IL-1beta, development of TMD may also lead to decreased IL-1ra and increased sIL-1RII in response to increasing IL-1. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:493 / 499
页数:7
相关论文
共 30 条
[1]
Interleukin-1,β interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides [J].
Alstergren, P ;
Benavente, C ;
Kopp, S .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2003, 61 (10) :1171-1178
[2]
Interleukin-1β in synovial fluid from the arthritic temporomandibular joint and ets relation to pain, mobility, and anterior open bite [J].
Alstergren, P ;
Ernberg, M ;
Kvarnstrom, M ;
Kopp, S .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 1998, 56 (09) :1059-1065
[3]
DETERMINATION OF TEMPOROMANDIBULAR-JOINT FLUID CONCENTRATIONS USING VITAMIN-B-12 AS AN INTERNAL STANDARD [J].
ALSTERGREN, P ;
APPELGREN, A ;
APPELGREN, B ;
KOPP, S ;
LUNDEBERG, T ;
THEODORSSON, E .
EUROPEAN JOURNAL OF ORAL SCIENCES, 1995, 103 (04) :214-218
[4]
Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist [J].
Arend, WP .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2001, 30 (05) :1-6
[5]
AREND WP, 1994, J IMMUNOL, V153, P4766
[6]
CHOMARAT P, 1995, J IMMUNOL, V154, P1432
[7]
CHEMOATTRACTANTS INDUCE RAPID RELEASE OF THE INTERLEUKIN-1 TYPE-II DECOY RECEPTOR IN HUMAN POLYMORPHONUCLEAR CELLS [J].
COLOTTA, F ;
ORLANDO, S ;
FADLON, EJ ;
SOZZANI, S ;
MATTEUCCI, C ;
MANTOVANI, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (06) :2181-2188
[8]
INTERLEUKIN-1 TYPE-II RECEPTOR - A DECOY TARGET FOR IL-1 THAT IS REGULATED BY IL-4 [J].
COLOTTA, F ;
RE, F ;
MUZIO, M ;
BERTINI, R ;
POLENTARUTTI, N ;
SIRONI, M ;
GIRI, JG ;
DOWER, SK ;
SIMS, JE ;
MANTOVANI, A .
SCIENCE, 1993, 261 (5120) :472-475
[9]
Colotta F, 1996, J IMMUNOL, V156, P2534
[10]
COLOTTA F, 1994, J BIOL CHEM, V269, P12403